3 Big Movers in Cancer Care -- Ariad Pharmaceuticals, Galena Biopharma, and Aratana Therapeutics
Ariad Pharmaceuticals (NASDAQ: ARIA), Galena Biopharma (NASDAQ: GALE), and Aratana Therapeutics (NASDAQ: PETX) have all served up a roller-coaster ride for shareholders in 2014.
Despite Dilution, Aratana Therapeutics Can Keep Climbing
Aratana Therapeutics recently announced conditional approval by the USDA of its lymphoma treatment for dogs, a big potential revenue driver.
3 Stocks You Must Follow This Morning: Cell Therapeutics Inc., Aratana Therapeutics Inc., and Therap
Cell Therapeutics, Aratana Therapeutics, and TherapeuticsMD could be three health care stocks worth watching today. Here’s why.
This Week in Biotech
An FDA approval, a mixed batch of clinical data, a welcome pipeline update, and an ongoing patent battle are this week's must-watch biotech stories.
A Year-End Look at 3 High-Flying Biotech IPOs of 2013: PETX, RCPT, STML
Aratana Therapeutics Inc., Receptos Inc., and Stemline Therapeutics Inc. are three biotech IPOs of 2013 that are finishing the year with strong gains. Can they continue soaring into 2014?
Why Aratana Therapeutics Inc. Shares Jumped
Aratana provides a pipeline update and shares ascend to the heavens. Should investors be howling with excitement or barking with displeasure?
3 Horrendous Health-Care Stocks This Week
Which health-care stocks might make Santa's naughty list for the past week? Enanta, Rockwell Medical, and Aratana rank at the top of that list.
4 Top-Performing Biotech IPOs of 2013
This was a year buyers could actually make money buying stocks of newly public companies.
Why Aratana Therapeutics Inc. Shares Clawed Higher
Aratana announces the purrrrrfect acquisition of Vet Therapeutics, but are shareholder expectations of the company now unrealistic?